Liraglutide, a GLP-1 receptor agonist used for diabetes and weight loss, has shown promise in reducing monthly migraine days in patients with obesity, independent of weight loss. A study presented at the 11th Congress of the European Academy of Neurology demonstrated a significant decrease in monthly headache days, improvement in Migraine Disability Assessment scores, and minimal adverse events, suggesting a potential weight-independent effect in migraine reduction.